Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAP-1002 · 2 trials · 9 indications
| Name | Type | Description |
|---|---|---|
| CAP-1002 | BIOLOGICAL | Peripheral infusion of 150 million cardiosphere-derived cells (CDCs) |
| Placebo | BIOLOGICAL | Matching placebo solution |
CAP-1002 is an investigational therapy being studied for COVID-19 and muscular dystrophies, including Duchenne muscular dystrophy. It is in Phase 2 clinical development and is not approved by the FDA.
CAP-1002 is being developed by Capricor Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CAPR.
CAP-1002 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any use.
CAP-1002 has been studied in two completed Phase 2 trials: NCT03406780 in patients with Duchenne muscular dystrophy and NCT04623671 in patients with COVID-19. Both trials are completed.
CAP-1002 is classified as a monoclonal antibody modality. It is being investigated for infectious disease and muscular dystrophy indications.